4TurktasH,UnsalM, TulekN, et al. Hepatotoxicity ofantiuberculosistherapy(rifampicin, isoniazidand and pyrazinamide) or viral hepatitis[J].Tuber Lung Dis, 1994,75:58-60.
4Tamim H, Iran i-Hakime N, Aoun JP, et al. Seroprevalence of hepatitis C virus (HCV) infection among blood donors : a hospital- based study [ J]. Transfus Aphere Sci, 2001,24 (1) :29-35.
5Kuniholm MH, Mark J, Aladashvili M, et al. Risk factors and al- gorithms to identify hepatitis C, hepatitis B, and HIV among Geor- gian tuberculosis patients. Int J Infect Dis, 2008,12 ( 1 ) :51-56.
6Dessing M1, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an l 1-year study [J].Tuber Lung Dis, 1996,77(4) :335-340.
7Teleman MD, Chee CB, Earnest A, et al. Hepatotoxicity of tuber- culosis chemotherapy under general programme conditions in Sin- gapore [J]. Int J Tuberc Lung Dis, 2002,6(8) :699-705.
8Ungo JR, Jones D, Ashkin D, et al. Antitubereulosis drug-in- duced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus [ J]. Am J Respir Cfit Care Med, 1998, 157(6 Pt 1) :1871-1876.
9Lomtadze N, Kupreishvili L, Salakaia A, et al. Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary Tuberculosis [ J ]. PLoS One, 2013(12) :e83892.
10Kwon YS, Koh WJ, Suh GY, et al. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy [ J]. Chest, 2007 ( 3 ) :803-808.
